Genmab ADR

GMABNASDAQ · USD
50.60USD0.00 (-1.47%)
9610

Genmab ADR (GMAB) Historical Volatility

GMAB's 30 day historical volatility is 83.49%, in the 94th percentile of readings over the past year. This is a high percentile, meaning Genmab ADR shares have swung far more than usual. GMAB's 30 day implied volatility sits at 47.25%, with an IV Rank of 18.65%, leaving IV 36.24 points below historical volatility. This means options are pricing in less movement than the stock has actually delivered, as of Nov 20, 2026.

Read more

Tracking GMAB historical volatility helps you see how much Genmab ADR's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, GMAB's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor GMAB 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.

Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. GMAB's 30 day historical volatility, or GMAB HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing GMAB's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies.

Historical Volatility

HV Percentile
94thHV Percentile
High

Historical movement is elevated versus the past year. The stock has been unusually active.

Historical Volatility (30d)83.49%

HV Percentile94th

Implied Volatility (30d)47.25%

IV Rank18.65%

IV Minus HV-36.24%

As of Nov 20, 2026

IV vs HV
Implied Volatility (IV) vs Historical Volatility (HV) over the past month.

As of Nov 20, 2026

IV - HV Difference
Difference between IV and HV over time. Positive values indicate IV > HV.

As of Nov 20, 2026

Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →